Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 14/20 | 0.51 |
| ▸ | MAPT | P10636 | 10/20 | 0.51 |
| ▸ | GSK3A | P49840 | 3/20 | 0.51 |
| ▸ | NTRK1 | P04629 | 2/20 | 0.43 |
| ▸ | RPS6KA2 | Q15349 | 1/20 | 0.42 |
| ▸ | AURKA | O14965 | 1/20 | 0.38 |
| ▸ | CDK1 | P06493 | 1/20 | 0.38 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.38 |
| ▸ | CDK2 | P24941 | 1/20 | 0.38 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.38 |
| ▸ | CGAS | Q8N884 | 1/20 | 0.38 |
| ▸ | SYK | P43405 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16703608 | 0.85 | GSK3B (0.70) | GSK3BMAPTGSK3ANTRK1RPS6KA2 | |
| SCHEMBL18089159 | 0.82 | GSK3B (0.75) | GSK3BMAPTGSK3A | |
| SCHEMBL18089116 | 0.81 | GSK3B (0.51) | GSK3BMAPTGSK3A | |
| SCHEMBL18089083 | 0.81 | GSK3B (0.54) | GSK3BMAPTGSK3A | |
| SCHEMBL18089093 | 0.77 | GSK3B (0.50) | GSK3BMAPTGSK3A | |
| SCHEMBL18089244 | 0.76 | GSK3B (0.54) | GSK3BMAPTGSK3A | |
| SCHEMBL18089158 | 0.76 | KDM4C (0.47) | GSK3BMAPTGSK3AAURKAAURKB | |
| SCHEMBL18089247 | 0.76 | GSK3B (0.53) | GSK3BMAPTGSK3A | |
| SCHEMBL18089143 | 0.75 | GSK3B (0.59) | GSK3BMAPTGSK3A | |
| SCHEMBL18089223 | 0.75 | GSK3B (0.64) | GSK3BMAPTGSK3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160272621-A1 | GSK-3 INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-09-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160272621-A1 | GSK-3 INHIBITORS | GSK3B, GSK3A, GSKIP | GSK3B 1/4885MAPT 90/4885GSK3A 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.